A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

September 24, 2019

Study Completion Date

January 9, 2020

Conditions
Hypertriglyceridemia
Interventions
DRUG

CaPre

4 x 1 g capsules administered orally once daily for 26 weeks

DRUG

Placebo

4 x 1 g capsules administered orally once daily for 26 weeks

Trial Locations (68)

10036

Research site, New York

10468

Research site, The Bronx

11413

Research site, Laurelton

12206

Research site, Albany

12553

Research site, New Windsor

19446

Research site, Lansdale

20110

Research site, Manassas

20230

Research site, Aguascalientes

20782

Research site, Hyattsville

21229

Research site, Baltimore

28655

Research site, Morganton

29340

Research site, Gaffney

29379

Research site, Union

29485

Research site, Summerville

30071

Research site, Peachtree Corners

30338

Research site, Dunwoody

31203

Research site, Chihuahua City

31406

Research site, Savannah

32205

Research site, Jacksonville

32277

Research site, Jacksonville

32720

Research site, DeLand

33016

Research site, Miami Lakes

33133

Research site, Miami

33134

Research site, Coral Gables

Research site, Miami

33144

Research site, Miami

33308

Research site, Fort Lauderdale

33756

Research site, Clearwater

35044

Research site, Childersburg

35216

Research site, Birmingham

38801

Research site, Tupelo

43302

Research site, Marion

48503

Research site, Flint

52242

Research site, Iowa City

60084

Research site, Wauconda

66210

Research site, Overland Park

68701

Research site, Norfolk

73112

Research site, Oklahoma City

77043

Research site, Houston

77074

Research site, Houston

77079

Research site, Houston

78028

Research site, Kerrville

78626

Research site, Georgetown

80132

Research site, Monument

80230

Research site, Culiacán

83712

Research site, Boise

84015

Research site, Clinton

84405

Research site, Ogden

89120

Research site, Las Vegas

89169

Research site, Las Vegas

90503

Research site, Torrance

90806

Research site, Long Beach

91360

Research site, Thousand Oaks

91436

Research site, Encino

92111

Research site, San Diego

04005

Research site, Biddeford

R2V4W3

Research site, Winnipeg

B3H2Y9

Research site, Halifax

L6T0G1

Research site, Brampton

L7R1A4

Research site, Burlington

N5W6A2

Research site, London

L3Y5G8

Research site, Newmarket

N7T4X3

Research site, Sarnia

G1N4V3

Research site, Québec

J1L0H8

Research site, Sherbrooke

06700

Research site, Mexico City

03300

Research site, Mexico City

06760

Research site, Mexico City

Sponsors
All Listed Sponsors
lead

Grace Therapeutics Inc.

INDUSTRY